Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 3 August 1990:
Vol. 249. no. 4968, pp. 537 - 540
DOI: 10.1126/science.2116663
Prev | Table of Contents | Next

Articles

Science, Vol 249, Issue 4968, 537-540
Copyright © 1990 by American Association for the Advancement of Science

articles

Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections

GB Pier, GJ Small, and HB Warren

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Animal Resource Center, Harvard Medical School, Boston, MA 02115.

Chronic endobronchial infection with mucoid Pseudomonas aeruginosa accounts for much of the morbidity and mortality in patients with cystic fibrosis (CF). Reduced morbidity is observed when infection is absent. Clinical investigations have implicated opsonizing antibody specific for the mucoid exopolysaccharide (MEP) surrounding these bacteria as a potential immunologic protective mechanism, whereas nonopsonizing antibody to MEP is not protective. Mice and rats immunized with doses of MEP that elicited opsonizing antibody had reduced levels of infection compared with nonimmune controls after intratracheal challenge with mucoid P. aeruginosa enmeshed in agar beads. Doses of MEP that elicited nonopsonizing antibody were not protective. Parallel experiments in which passive transfer of polyclonal and monoclonal opsonizing and nonopsonizing antibody were used yielded similar results. These data indicate that MEP-specific opsonizing antibody can protect against chronic P. aeruginosa infection in this model of disease.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Pseudomonas aeruginosa AlgR Controls Cyanide Production in an AlgZ-Dependent Manner.
W. L. Cody, C. L. Pritchett, A. K. Jones, A. J. Carterson, D. Jackson, A. Frisk, M. C. Wolfgang, and M. J. Schurr (2009)
J. Bacteriol. 191, 2993-3002
   Abstract »    Full Text »    PDF »
Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies.
I Kukavica-Ibrulj and R C Levesque (2008)
Lab Anim 42, 389-412
   Abstract »    Full Text »    PDF »
Opsonic Antibodies to Enterococcus faecalis Strain 12030 Are Directed against Lipoteichoic Acid..
C. Theilacker, Z. Kaczynski, A. Kropec, F. Fabretti, T. Sange, O. Holst, and J. Huebner (2006)
Infect. Immun. 74, 5703-5712
   Abstract »    Full Text »    PDF »
Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate..
N. Kashef, Q. Behzadian-Nejad, S. Najar-Peerayeh, K. Mousavi-Hosseini, M. Moazzeni, and G. E. Djavid (2006)
J. Med. Microbiol. 55, 1441-1446
   Abstract »    Full Text »    PDF »
Role of an Alginate Lyase for Alginate Transport in Mucoid Pseudomonas aeruginosa.
S. Jain and D. E. Ohman (2005)
Infect. Immun. 73, 6429-6436
   Abstract »    Full Text »    PDF »
Human Monoclonal Antibodies to Pseudomonas aeruginosa Alginate That Protect against Infection by Both Mucoid and Nonmucoid Strains.
G. B. Pier, D. Boyer, M. Preston, F. T. Coleman, N. Llosa, S. Mueschenborn-Koglin, C. Theilacker, H. Goldenberg, J. Uchin, G. P. Priebe, et al. (2004)
J. Immunol. 173, 5671-5678
   Abstract »    Full Text »    PDF »
Construction and Characterization of a Pseudomonas aeruginosa Mucoid Exopolysaccharide-Alginate Conjugate Vaccine.
C. Theilacker, F. T. Coleman, S. Mueschenborn, N. Llosa, M. Grout, and G. B. Pier (2003)
Infect. Immun. 71, 3875-3884
   Abstract »    Full Text »    PDF »
Lung Infections Associated with Cystic Fibrosis.
J. B. Lyczak, C. L. Cannon, and G. B. Pier (2002)
Clin. Microbiol. Rev. 15, 194-222
   Abstract »    Full Text »    PDF »
Role of Alginate O Acetylation in Resistance of Mucoid Pseudomonas aeruginosa to Opsonic Phagocytosis.
G. B. Pier, F. Coleman, M. Grout, M. Franklin, and D. E. Ohman (2001)
Infect. Immun. 69, 1895-1901
   Abstract »    Full Text »    PDF »
Prophylactic and Therapeutic Efficacy of Antibodies to a Capsular Polysaccharide Shared among Vancomycin-Sensitive and -Resistant Enterococci.
J. Huebner, A. Quaas, W. A. Krueger, D. A. Goldmann, and G. B. Pier (2000)
Infect. Immun. 68, 4631-4636
   Abstract »    Full Text »    PDF »
Pulmonary Outcome in Cystic Fibrosis Is Influenced Primarily by Mucoid Pseudomonas aeruginosa Infection and Immune Status and Only Modestly by Genotype.
R. B. Parad, C. J. Gerard, D. Zurakowski, D. P. Nichols, and G. B. Pier (1999)
Infect. Immun. 67, 4744-4750
   Abstract »    Full Text »    PDF »
Characterization of Chronic Bronchopulmonary Pseudomonas aeruginosa Infection in Resistant and Susceptible Inbred Mouse Strains.
M. Tam, G. Jackson Snipes, and M. M. Stevenson (1999)
Am. J. Respir. Cell Mol. Biol. 20, 710-719
   Abstract »    Full Text »
Production and Characterization of a Set of Mouse-Human Chimeric Immunoglobulin G (IgG) Subclass and IgA Monoclonal Antibodies with Identical Variable Regions Specific for Pseudomonas aeruginosa Serogroup O6 Lipopolysaccharide.
M. J. Preston, A. A. Gerceker, M. E. Reff, and G. B. Pier (1998)
Infect. Immun. 66, 4137-4142
   Abstract »    Full Text »    PDF »
Microbial Pathogenesis in Cystic Fibrosis: Pulmonary Clearance of Mucoid Pseudomonas aeruginosa and Inflammation in a Mouse Model of Repeated Respiratory Challenge.
H. Yu, M. Hanes, C. E. Chrisp, J. C. Boucher, and V. Deretic (1998)
Infect. Immun. 66, 280-288
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)